

ASX Announcement (ASX:HLS)

ASX Limited
Market Announcements Office
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000

19 April 2023

Electronic delivery of Healius' Target's Statement

On 20 March 2023, Healius Limited (ASX:HLS) (**Healius**) received an unsolicited, highly conditional all scrip reverse takeover offer from Australian Clinical Labs Limited (ASX:ACL) (**ACL**) (the **ACL Offer**). On 14 April 2023, ACL lodged a replacement bidder's statement for the ACL Offer (**Replacement Bidder's Statement**). Further details of the ACL Offer are contained in the Replacement Bidder's Statement.

Healius has previously advised its shareholders to **TAKE NO ACTION** in relation to the ACL Offer and wait until they receive and consider Healius' target's statement (**Target's Statement**), which will include full details of the Healius Board's recommendation, before deciding whether to accept or reject the Offer. The Target's Statement is expected to be released on or around 5 May 2023.

ASIC has granted Healius relief from the usual requirements under section 648C of the *Corporations Act 2001* (Cth) to send the Target's Statement to Healius shareholders by post. This means that when the Target's Statement is released:

- (a) if Healius shareholders have nominated an email address to receive communications from Healius, then they will receive an email to their nominated email address with a link to an electronic copy of the Target's Statement; and
- (b) if Healius shareholders have not nominated an email address to receive communications from Healius, then they will receive a letter from Healius to their registered postal address, which will contain details of a link to an electronic copy of the Target's Statement.

Healius applied for this relief to ensure that Healius shareholders receive the Target's Statement in accordance with their preferences, to ensure quick and reliable delivery of the Target's Statement and to avoid unnecessary financial and environmental costs associated with printing and mailing the Target's Statement to shareholders who do not wish to receive hard copy documents.

Healius shareholders may also request a hard copy of the Target's Statement be sent to them (if in Australia, by pre-paid ordinary post, or, if outside Australia, by pre-paid airmail post) by contacting the Healius Shareholder Information Line on 1300 103 401 (if in Australia) or +61 2 9066 4063 (if outside Australia) from 9am to 5pm Monday to Friday (Sydney time).

ASIC has advised that the fact that it has granted this relief in connection with the ACL Offer should not be taken as a reflection of ASIC's views on any other aspect of the ACL Offer.

The release of this announcement has been authorised by the Healius Chair.

ENDS

For further information contact:

Analysts and market

Janet Payne
Group Executive, Corporate Affairs
Mobile: +61 409 995 517

Media

Andrew Butcher
Bespoke Approach
Mobile: +61 400 841 088

Shareholders Information Line

Phone: 1300 103 401 (within Australia)
Phone: +61 2 9066 4063 (outside Australia)

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,000+ employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.